Combined Photodynamic Therapy With Intravitreal Bevacizumab Injections for Polypoidal Choroidal Vasculopathy: Long-term Visual Outcome

PURPOSE: To evaluate the long-term visual outcome after combination therapy of photodynamic therapy (PDT) with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy (PCV). DESIGN: Retrospective observational study. METHODS: The medical records of 34 eyes (34 patients) with naive PCV who were treated with combination therapy were analyzed. All patients completed at least 3 years of follow-up. All clinical data, including age, best-corrected visual acuity (BCVA, logarithm of the minimal angle of resolution [logMARD, imaging data of fluorescein angiography, indocyanine green angiography, and optical coherence tomography, were investigated. RESULTS: During a mean follow-up period of 46.8 5.2 months, a mean of 1.4 0.71 times of PDT and 9.2 6.6 intravitreal bevacizumab injections were performed. During follow-up, 21 eyes (61.8%) showed at least 1 recurrence. Mean BCVA was 0.59 0.35 logMAR (20/77 Snellen equivalent) at baseline and 0.39 0.34 logMAR (20/49 Snellen equivalent) at 3 years (P = .004). At 3 years, 14 patients (41.2%) gained 0.3 logMAR or more BCVA and 4 patients (11.8%) lost 0.3 logMAR or more BCVA than baseline. Baseline polyp size (13 = .551; P = .005) and location of polyps (13 = .400; P = .033) were significantly correlated with long-term visual outcome after combination therapy for PCV. CONCLUSIONS: Combination therapy of PDT with intravitreal bevacizumab injections showed favorable visual outcomes, and significant visual improvement was maintained in PCV patients. A total of 88.2% of patients avoided visual loss at 3 years after treatments. Largest polyp size at baseline and location of polypoidal lesions were prognostic factors for long-term visual outcomes in these patients.